A subscription to JoVE is required to view this content. Sign in or start your free trial.
The protocol allows the generation of a pure adipocyte population from induced pluripotent stem cells (iPSCs). Retinoic acid is used to differentiate iPSCs into mesenchymal stem cells (MSCs) which are used for producing adipocytes. Then, a sorting approach based on Nile red staining is used to obtain pure adipocytes.
Recent advances in induced pluripotent stem cell (iPSC) technology have allowed the generation of different cell types, including adipocytes. However, the current differentiation methods have low efficiency and do not produce a homogenous population of adipocytes. Here, we circumvent this problem by using an all-trans retinoic-based method to produce mesenchymal stem cells (MSCs) in high yield. By regulating pathways governing cell proliferation, survival, and adhesion, our differentiation strategy allows the efficient generation of embryonic bodies (EBs) that differentiate into a pure population of multipotent MSCs. The high number of MSCs generated by this method provides an ideal source for generating adipocytes. However, sample heterogeneity resulting from adipocyte differentiation remains a challenge. Therefore, we used a Nile red-based method for purifying lipid-bearing mature adipocytes using FACS. This sorting strategy allowed us to establish a reliable way to model adipocyte-associated metabolic disorders using a pool of adipocytes with reduced sample heterogeneity and enhanced cell functionality.
Mesenchymal stem cells (MSCs) act as an effective transitory resource for producing cells of mesodermal origin like adipocytes, osteocytes, and chondrocytes, which could be further used for modeling their respective genetic disorders. However, previous approaches relied on attaining these MSCs from adult tissues1, which imposed the challenge of obtaining them in high numbers from the donors, and the limitation of keeping them functionally viable in suboptimal in vitro culture conditions1,2. These obstacles have produced a great demand of having a protocol for generating MSCs
The study has been approved by the appropriate institutional research ethics committee and performed following the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The protocol was approved by the Institutional Review Board (IRB) of HMC (no. 16260/16) and QBRI (no. 2016-003). This work is also optimized for hESCs such as H1 and H9. Blood samples were obtained from healthy individuals with full informed consent. The iPSCs are generated from periph.......
Schematic and morphology of cells during mesenchymal differentiation: Differentiation of iPSCs into MSCs involves various stages of development spanning across EB formation, MSC differentiation, and MSC expansion (Figure 1). During these stages of development, cells acquire various morphology owing to the different stimulatory chemicals they are subjected to. Upon initiating differentiation, cells are plated in suspension and are expected to be round, with defined cell borders, while being s.......
This protocol holds paramount importance due to its ability to provide MSCs in high yield and efficiency. This mass-scale production of MSCs was made possible by transient incubation of iPSCs-derived EBs with 10 µM of RA14,15. Transient treatment with 10 µM of RA enhanced the MSC yield by 11.2 to 1542 folds14,15, with this protocol being applicable on both iPSCs and hPSCs. At this dose and durat.......
This work was funded by a grant from Qatar National Research Fund (QNRF) (Grant No. NPRP10-1221-160041). Maryam Aghadi was supported by GSRA scholarship from Qatar National Research Fund (QNRF).
....Name | Company | Catalog Number | Comments |
Adiponectin | Abcam | ab22554 | Adipocyte maturation marker |
anti-CD105 | BD Pharmingen | 560839 | MSC differentiation marker |
anti-CD14 | BD Pharmingen | 561712 | MSC differentiation marker |
anti-CD19 | BD Pharmingen | 555415 | MSC differentiation marker |
anti-CD34 | BD Pharmingen | 555824 | MSC differentiation marker |
anti-CD44 | abcam | ab93758 | MSC differentiation marker |
anti-CD45 | BD Pharmingen | 560975 | MSC differentiation marker |
anti-CD73 | BD Pharmingen | 550256 | MSC differentiation marker |
anti-CD90 | BD Pharmingen | 555596 | MSC differentiation marker |
bFGF | R&D | 233-FP | MSC culture media supplement |
C/EBPA | Abcam | ab40761 | Adipocyte maturation marker |
Dexamethasone | Torics | 1126 | Adipocyte differentiation media supplement |
FABP4 | Abcam | ab93945 | Adipocyte maturation marker |
Fetal bovine serum | ThermoFisher | 10082147 | MSC culture media supplement |
Glutamax | ThermoFisher | 35050-061 | MSC culture media supplement |
IBMX | Sigma Aldrich | I5879 | Adipocyte differentiation media supplement |
Indomethacin | Sigma Aldrich | I7378 | Adipocyte differentiation media supplement |
Insulin | Sigma Aldrich | 91077C | Adipocyte differentiation media supplement |
Knockout DMEM | ThermoFisher | 12660012 | Basal media for preparing matrigel |
Low glucose DMEM | ThermoFisher | 11885084 | MSC culturing media |
Matrigel | Corning | 354230 | Coating matrix |
MEM-alpha | ThermoFisher | 12561056 | Adipocyte differentiation media |
Nilered | Sigma Aldrich | 19123 | Sorting marker for adipocyte |
Penicillin | ThermoFisher | 15140122 | MSC/Adipocyte media supplement |
Phosphate-buffered saline | ThermoFisher | 14190144 | wash buffer |
Pierceâ„¢ 20X TBS Buffer | Thermo Fisher | 28358 | wash buffer |
PPARG | Cell Signaling Technology | 2443 | Adipocyte maturation marker |
ReLeSR | Stem Cell Technologies | 5872 | Dissociation reagent |
Retinoic acid | Sigma Aldrich | R2625 | MSC differentiation media supplement |
Rock inhibitor | Tocris | 1254/10 | hPSC culture media supplement |
Roziglitazone | Sigma Aldrich | R2408 | Adipocyte differentiation media supplement |
StemFlex | ThermoFisher | A334901 | hPSC culture media |
Triton | Thermo Fisher | 28314 | Permebealization reagent |
Trypsin | ThermoFisher | 25200072 | Dissociation reagent |
Tween 20 | Sigma Aldrich | P7942 | Wash buffer |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved